GlassScriptPhysician profile
Jacek Pinski
NPI 1720014160
$671,784.90
in general payments reported to CMS, 2019-2025
29 companies · $75K in 2025
The $75K reported for 2025 was more than what 97% of Medical Oncology providers received nationally (typical 2025 total: $1,158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $146K · 2020: $67K · 2021: $38K · 2022: $91K · 2023: $126K · 2024: $129K · 2025: $75K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $261K · Travel and Lodging: $39K · Consulting Fee: $15K · Food and Beverage: $13K · Education: $590.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $261,249.52 |
| Travel and Lodging | $38,887.24 |
| Consulting Fee | $15,335.00 |
| Food and Beverage | $13,476.15 |
| Education | $589.82 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $181,314.82 | 2019-2025 | |
| Janssen Biotech, INC. | $133,422.09 | 2019-2025 | Erleada, Akeega, Rybrevant |
| Bayer Healthcare Pharmaceuticals INC. | $84,086.04 | 2019-2023 | |
| Astellas Pharma US INC | $48,702.51 | 2019-2025 | Xtandi, Padcev |
| Sumitomo Pharma America, INC. | $45,642.77 | 2023-2025 | Orgovyx |
| Abbvie INC. | $42,175.77 | 2019-2021 | |
| Astrazeneca Pharmaceuticals LP | $39,800.61 | 2020-2025 | Lynparza |
| Merck Sharp & Dohme LLC | $22,775.58 | 2023-2025 | Keytruda, Lynparza |
| Myovant Sciences INC. | $20,958.37 | 2021-2022 | |
| Dendreon Pharmaceuticals LLC | $14,669.13 | 2019-2025 | Provenge |
| Amgen INC. | $10,326.72 | 2019-2020 | |
| Seagen INC. | $8,539.72 | 2020-2025 | Padcev |
| Progenics Pharmaceuticals, INC. | $7,791.12 | 2025 | |
| Genzyme Corporation | $5,633.84 | 2020-2023 | |
| Clovis Oncology, INC. | $2,600.00 | 2020 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Scientific Affairs, LLC | $1,332.97 | 2019-2025 | Erleada, Akeega |
| Aveo Pharmaceuticals, INC. | $689.92 | 2022-2025 | Fotivda |
| Exelixis INC. | $444.96 | 2023-2024 | Cabometyx |
| Roche Diagnostics Corporation | $270.93 | 2022-2023 | |
| Tolmar, INC. | $128.86 | 2023-2025 | Rubraca, Eligard |
| Novartis Pharmaceuticals Corporation | $125.34 | 2025 | |
| Pharmaand Gmbh | $80.75 | 2025 | Rubraca |
| Emd Serono, INC. | $65.44 | 2024 | |
| Caris Mpi, INC. | $60.65 | 2025 | Mi Cancer Seek |
| Daiichi Sankyo INC. | $50.80 | 2025 | Datroway |
| Eisai INC. | $39.60 | 2024 | |
| Regeneron Healthcare Solutions, INC. | $35.73 | 2022 | |
| Genentech USA, INC. | $19.86 | 2020 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jacek Pinski listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.